TRACON Pharmaceuticals announced that its Phase 3 TAPPAS trial evaluating TRC105 in combination with Votrient in patients with advanced or metastatic angiosarcoma was terminated for futility based on the recommendation of the Independent Data Monitoring Committee following its review of interim unblinded safety and efficacy data from more than 120 patients enrolled in the trial at the time of the analysis. TRACON will work with investigators to appropriately conclude the study in a manner consistent with the best interests of each patient. Data from this study will be analyzed and submitted for presentation at an upcoming scientific congress.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.